TW200616612A - Method for the teatment of polycystic kidney disease field of invention - Google Patents

Method for the teatment of polycystic kidney disease field of invention

Info

Publication number
TW200616612A
TW200616612A TW094133944A TW94133944A TW200616612A TW 200616612 A TW200616612 A TW 200616612A TW 094133944 A TW094133944 A TW 094133944A TW 94133944 A TW94133944 A TW 94133944A TW 200616612 A TW200616612 A TW 200616612A
Authority
TW
Taiwan
Prior art keywords
kidney disease
polycystic kidney
teatment
disease field
inhibitor
Prior art date
Application number
TW094133944A
Other languages
English (en)
Chinese (zh)
Inventor
Philip Frost
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200616612A publication Critical patent/TW200616612A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094133944A 2004-10-08 2005-09-29 Method for the teatment of polycystic kidney disease field of invention TW200616612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08

Publications (1)

Publication Number Publication Date
TW200616612A true TW200616612A (en) 2006-06-01

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094133944A TW200616612A (en) 2004-10-08 2005-09-29 Method for the teatment of polycystic kidney disease field of invention

Country Status (12)

Country Link
US (1) US20060079515A1 (https=)
EP (1) EP1796727A2 (https=)
JP (1) JP2008515913A (https=)
CN (1) CN101102757A (https=)
AR (1) AR052221A1 (https=)
AU (1) AU2005294258A1 (https=)
BR (1) BRPI0516533A (https=)
CA (1) CA2580864A1 (https=)
MX (1) MX2007004001A (https=)
PE (1) PE20060681A1 (https=)
TW (1) TW200616612A (https=)
WO (1) WO2006042100A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) * 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
JP5931876B2 (ja) 2010-08-26 2016-06-08 シンフォニー エボリューション， インコーポレイテッド 多発性嚢胞腎を処置するためのレセプタータイプキナーゼの調節因子の使用
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
AR037438A1 (es) * 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos

Also Published As

Publication number Publication date
AR052221A1 (es) 2007-03-07
US20060079515A1 (en) 2006-04-13
AU2005294258A1 (en) 2006-04-20
CN101102757A (zh) 2008-01-09
EP1796727A2 (en) 2007-06-20
PE20060681A1 (es) 2006-08-28
WO2006042100A2 (en) 2006-04-20
BRPI0516533A (pt) 2008-09-09
MX2007004001A (es) 2007-05-11
WO2006042100A3 (en) 2007-06-07
JP2008515913A (ja) 2008-05-15
CA2580864A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
TW200616612A (en) Method for the teatment of polycystic kidney disease field of invention
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2006105081A3 (en) Pharmacokinetically improved compounds
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2006091395A3 (en) Inhibitors of akt activity
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2007079164A3 (en) Protein kinase inhibitors
WO2007115289A3 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
WO2007139960A3 (en) Compounds that modulate hsp90 activity and methods for identifying same
NO20092609L (no) Tannate salt of rasagiline
WO2006138660A3 (en) Sphingosine kinase inhibitors
WO2004073653A3 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2008049856A3 (en) Methods of treating pain using cdk inhibitors
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2006125616A3 (en) Pyrimidine-based cdk inhibitors for treating pain
WO2006110638A3 (en) Inhibitors of akt activity
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment